Increased Risk for Breast Cancer in Shift Workers Possibly Associated with Epigenetic Changes in Circadian Pathway

TON - March 2017, Vol 10, No 2 - Breast Cancer
Meg Barbor, MPH

Cape Town, South Africa—Occupational factors such as shift work disrupt circadian rhythm and can increase breast cancer risk, and the International Agency for Research on Cancer (the World Health Organization’s source for information about cancer) has classified shift work as a possible carcinogen. However, according to researchers at the National Institute of Occupational Health in Oslo, Norway, and the Nofer Institute of Occupational Medicine in Lodz, Poland, the mechanisms of increased cancer risk caused by shift work are not fully understood.

Circadian disruption may affect epigenetic factors such as 5-methyl cytosine methylation in DNA. DNA hypermethylation is associated with increased cancer risk if it occurs in tumor suppressor genes, and some circadian genes are known to function as tumor suppressor genes. The re­searchers, led by Shan Zienolddiny from the National Institute of Occupational Health, hypothesized that these aberrant epigenetic modifications caused by circadian disruption may be involved in the development of breast cancer.

The team conducted a nested breast cancer case-control study of female nurses working night shifts and presented their results in a poster at the American Association for Cancer Research International Conference on New Frontiers in Cancer Research. Changes in methylation levels in a number of core circadian and melatonin receptor genes were analyzed in 352 patients with breast cancer and 355 healthy controls.

Significantly higher methylation in the MTNR1A gene was observed in patients with cancer than in controls, and PR-A methylation was significantly increased in night workers compared with day workers. Based on these data, the investigators concluded that changes in methylation status of the genes that regulate circadian rhythm may be associated with increased breast cancer risk in workers with consecutive night shifts. However, further research is needed on the effects of work schedules on epigenetic changes.—MB

Related Items
Long-Term Data from the TEAM Trial Support Individualized Adjuvant Endocrine Therapy Strategy for Postmenopausal Women with HR-Positive Early Breast Cancer
TON Web Exclusives published on December 28, 2017 in Breast Cancer
Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2
TON Web Exclusives published on December 28, 2017 in Breast Cancer
Results of DATA Study Failed to Show Benefits for Extended Endocrine Therapy in Women with Breast Cancer
TON Web Exclusives published on December 28, 2017 in Breast Cancer
BRCA1/2 Status Affects Response to Polychemotherapy in Triple-Negative Breast Cancer
TON Web Exclusives published on December 28, 2017 in Breast Cancer
Do Hormonal Contraceptives Increase the Risk for Breast Cancer?
TON Web Exclusives published on December 28, 2017 in Breast Cancer
HER2 CAR T-Cell Delivery for Treating Multifocal Brain Metastases
TON Web Exclusives published on December 28, 2017 in Breast Cancer
Questions About Treating Patients Using a CDK4/6 Inhibitor
Matthew P. Goetz, MD
Conference Correspondent  published on December 10, 2017 in SABCS 2017 - Breast Cancer, Breast Cancer, Video
The Use of Chemotherapy in the Metastatic Setting
Matthew P. Goetz, MD
Conference Correspondent  published on December 10, 2017 in SABCS 2017 - Breast Cancer, Breast Cancer, Video
The Mechanism of Action of CDK4/6 Inhibitors
Matthew P. Goetz, MD
Conference Correspondent  published on December 10, 2017 in SABCS 2017 - Breast Cancer, Breast Cancer, Video
CDK4/6 Inhibitors in HER2+ Metastatic Breast Cancer
Matthew P. Goetz, MD
Conference Correspondent  published on December 10, 2017 in SABCS 2017 - Breast Cancer, Breast Cancer, Video
Last modified: March 14, 2017